Arthropathy of Knee Joint
Conditions
Brief summary
The current standard for rehabilitation after TKA consists of guided exercise therapy for up to 12 weeks after surgery. This includes inpatient, home, and outpatient therapy. The surgery and rehabilitation are highly successful at reducing or eliminating pain experienced preoperatively. However, quadriceps femoris muscle (QFM) strength, overall function, and knee range of motion are often worse than preoperative levels for as long as 6 months after surgery and in some cases may persist for many years after that. Such quadriceps strength impairments after TKA have been largely attributed to voluntary activation deficits and can lead to a decrease in functional performance such as decreased gait speed, decreased balance which can lead to falls, and decreased stair climbing & chair rise abilities. Since therapy alone does not adequately restore or improve upon the preoperative functional capabilities in a consistent and timely manner, it has been suggested that NMES used adjunctively with postoperative rehabilitation will alleviate the quadriceps muscle activation deficits. Early NMES use after TKA has been shown to: reduce knee extensor lag, increase walking speed, and improve QFM strength, knee range of motion, and function. However, NMES initiated one month after TKA did not lead to improved QFM strength or function beyond the standard benefits gained from exercise alone, thus suggesting that the timing of NMES application after TKA is important. It has previously been shown that preoperative QFM strength is predictive of postoperative function \[6\] but the benefit of prehabilitation remains in question. To date, there has only been one pilot study assessing the benefits of NMES when initiated preoperatively. This study only included 14 patients (9 NMES, 5 control) but was able to show that preoperative NMES usage may lead to greater QFM strength gains after TKA. Therefore, it will be important to assess the benefits of NMES both preoperatively and postoperatively in order to determine how it will be most beneficial to TKA patients.
Detailed description
The study duration will be until 12 weeks ± 1 week postoperatively. Data will be collected (1) 4 weeks preoperatively, (2) prior to hospital admission for TKA, and (3) at 3, 6, and 12 weeks postoperatively. The research coordinator at the site will identify, recruit, and prospectively follow the 66 patients at his/her site. All data will be entered and maintained in REDCap, an electronic data capture tools hosted at Cleveland Clinic. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. Only members of the study team (i.e. the personnel listed on the institutional review board (IRB) application) will have access to protected health information of patients included in this study. Pretreatment Assessments Before treatment, the following assessments/tests will be performed and the results will be recorded on the appropriate pages of the (case report form) CRF, and or Microsoft excel, Microsoft Word, and REDCap: * Informed consent * Age, gender, height/weight/(body mass index) BMI * Concomitant diseases * Physical examination * Baseline range of motion of affected knee * Baseline timed up and go test (TUG test, detailed in Appendix A and as described by Podsiadlo et al.) * Baseline Stair Climb test * Baseline QFM strength * Baseline Modified Knee Injury and Osteoarthritis Outcome Score (KOOS) and Veterans Rand 12(VR-12) assessments * Baseline VAS (visual analog scale)pain score * Current medications * Any use of ambulation assist device Presurgery Assessments Before surgery, the following assessments/tests will be performed and the results will be recorded on the appropriate pages of the CRF, and or Microsoft excel, Microsoft Word, and REDCap: * Device usage patterns (thru app for preop NMES group) * Range of motion of affected knee * TUG test * Stair Climb test * QFM strength * Modified KOOS and VR-12 assessments * VAS pain score * Current medications * Activity levels using Misfit Wearables® fitness monitor will be uploaded and incorporated into online app Operative Assessments The following will be collected from the Operative and Anesthesia Records and recorded on the appropriate pages of the CRF, and or Microsoft excel, Microsoft Word, and REDCap: * Surgeon name * Approach used * Randomization assignment * Diagnosis * Length of surgery * Estimated blood loss * Type of anesthesia * Implant type Postoperative Assessments After surgery, one or more of the following will be collected through the online app and at follow-up visits. * Device usage patterns (thru app) * Range of motion of affected knee (thru app and at follow-up) * TUG test * Stair Climb test * QFM strength * Modified KOOS and VR-12 assessments * VAS pain score * Length of stay (hospital, extended care facility) * 90 day readmission rate * Discharge Disposition (home vs skilled nursing facility vs inpatient rehabilitation) * Patient Satisfaction measures * Any use of an ambulation assist aid * Activity levels using Misfit Wearables® fitness monitor will be uploaded and incorporated into online app As a last resort, if a patient is unable to keep one of these appointments, he/she will be either be mailed or emailed the patient reported outcome forms so the patient can fill them out. The patient will date and time the forms. Participants will then send the form back in a pre-addressed envelope. The patients email will be verified by the patient during a clinical visit to ensure accuracy of the correct recipient. Patients not responding to the initial mailer will be contacted by phone and forms may be administered over the phone. The mailers and/or phone calls will allow us to collect all data except the physical function measures. All data will be entered and maintained in Redcap
Interventions
a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
Sponsors
Study design
Eligibility
Inclusion criteria
1. Patients undergoing unilateral primary total knee arthroplasty 2. Patients who are between the ages of 18 - 85 years 3. Patient has signed informed consent 4. Patient has access to a smartphone or tablet (Android or iOS)
Exclusion criteria
1. BMI ≥ 40 2. Inflammatory arthritis 3. Patients who are expected to be in extended care facilities after surgery 4. Patients who have used an at-home NMES device in the past 5. Preoperative daily use of narcotics (i.e., high tolerance) 6. Already enrolled in another research study, including the present study for contralateral knee 7. Other lower-extremity orthopaedic conditions which could interfere with limb function, especially those with significant pain requiring daily analgesic intake 8. Patients with concurrent abdominal, inguinal or femoral hernias 9. Cutaneous lesions in areas of electrode pad placement 10. Patients with a history of epilepsy 11. Patients with a cardiac pacemaker/defibrillator 12. Allergy to adhesives 13. Inability to meet follow-up visits required for the study 14. Patients who are a risk for poor compliance or have a poor understanding of the use of the NMES device 15. Condition deemed by physician or medical staff to be non-conducive to patient's ability to complete the study, or a potential risk to the patient's health and well-being
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs) | 6 weeks | measure change in muscle strength (QFM) - difference from baseline measure to 6 weeks postoperative |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analogue Scale (VAS) Pain Level (0-10 Scale) | 12 weeks | Differences in VAS scores between the treatment groups from baseline to 12 weeks postop. Higher score represents worse pain. |
| Hospital Length of Stay (Days) | 12 weeks | differences in length of stay between the treatment groups |
| Number of Patients Discharged to Extended Care Facility | 12 weeks | Patent discharge other than home to extended care facility |
| Knee Active Range of Motion (Extension, Flexion) in Degrees | 12 weeks | Measure rage of motion differences between the treatment groups |
| Number of Outpatient Therapy Visits (Patient Questionnaire) | 12 weeks | Difference in number of outpatient therapy visits among the treatment groups |
| KOOS - PS | 12 weeks | Functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS) Physical Function Shortform (PS) questionnaire. Change in total score from baseline to 12 weeks postoperative score. Minimum value is 0, maximum value is 100, and higher values mean greater improvement over baseline total score. |
| KOOS Pain | 12 weeks | Measure pain at 12 weeks postoperative using Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain subscore. Change in total score from baseline to 12 weeks postoperative score. Minimum value is 0, maximum value is 100, and higher values mean greater improvement over baseline total score. |
| Number of Patients Readmitted to Hospital | 12 weeks | Number of all-cause readmissions to the hospital |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| NMES Preoperative and Postoperative Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study
CyMedica Orthopedics QB1 e-vive™ system: a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA). | 12 |
| NMES Postoperative Only Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study
CyMedica Orthopedics QB1 e-vive™ system: a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA). | 12 |
| No Intervention Subject will not be given device and will undergo the standard rehab protocol alone | 22 |
| Total | 46 |
Baseline characteristics
| Characteristic | NMES Postoperative Only | No Intervention | Total | NMES Preoperative and Postoperative |
|---|---|---|---|---|
| Age, Continuous | 66.6 years STANDARD_DEVIATION 6.3 | 64.5 years STANDARD_DEVIATION 7.6 | 64.9 years STANDARD_DEVIATION 6.7 | 64.0 years STANDARD_DEVIATION 5.2 |
| Race (NIH/OMB) American Indian or Alaska Native | — | — | 0 Participants | — |
| Race (NIH/OMB) Asian | — | — | 0 Participants | — |
| Race (NIH/OMB) Black or African American | — | — | 0 Participants | — |
| Race (NIH/OMB) More than one race | — | — | 0 Participants | — |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | — | — | 0 Participants | — |
| Race (NIH/OMB) Unknown or Not Reported | — | — | 0 Participants | — |
| Race (NIH/OMB) White | — | — | 0 Participants | — |
| Region of Enrollment United States | 12 participants | 22 participants | 46 participants | 12 participants |
| Sex: Female, Male Female | 9 Participants | 17 Participants | 35 Participants | 9 Participants |
| Sex: Female, Male Male | 3 Participants | 5 Participants | 11 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 22 | 0 / 22 | 0 / 22 |
| other Total, other adverse events | 0 / 22 | 0 / 22 | 1 / 22 |
| serious Total, serious adverse events | 0 / 22 | 0 / 22 | 0 / 22 |
Outcome results
Quadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs)
measure change in muscle strength (QFM) - difference from baseline measure to 6 weeks postoperative
Time frame: 6 weeks
Population: Numbers do not match Participant Flow because data were missing.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NMES Preoperative and Postoperative | Quadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs) | 3.35 lbs | Standard Deviation 20.7 |
| NMES Postoperative Only | Quadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs) | 15.95 lbs | Standard Deviation 14.61 |
| Control - no NMES | Quadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs) | -5.48 lbs | Standard Deviation 16.53 |
Hospital Length of Stay (Days)
differences in length of stay between the treatment groups
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NMES Preoperative and Postoperative | Hospital Length of Stay (Days) | 1.83 days | Standard Deviation 0.72 |
| NMES Postoperative Only | Hospital Length of Stay (Days) | 1.75 days | Standard Deviation 0.45 |
| Control - no NMES | Hospital Length of Stay (Days) | 1.68 days | Standard Deviation 0.78 |
Knee Active Range of Motion (Extension, Flexion) in Degrees
Measure rage of motion differences between the treatment groups
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NMES Preoperative and Postoperative | Knee Active Range of Motion (Extension, Flexion) in Degrees | 0.50 degrees | Standard Deviation 13.22 |
| NMES Postoperative Only | Knee Active Range of Motion (Extension, Flexion) in Degrees | 6.67 degrees | Standard Deviation 15.4 |
| Control - no NMES | Knee Active Range of Motion (Extension, Flexion) in Degrees | -1.50 degrees | Standard Deviation 12.93 |
KOOS Pain
Measure pain at 12 weeks postoperative using Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain subscore. Change in total score from baseline to 12 weeks postoperative score. Minimum value is 0, maximum value is 100, and higher values mean greater improvement over baseline total score.
Time frame: 12 weeks
Population: Numbers do not match Participant Flow because data were missing.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NMES Preoperative and Postoperative | KOOS Pain | 72.22 z-score | Standard Deviation 19.64 |
| NMES Postoperative Only | KOOS Pain | 78.89 z-score | Standard Deviation 16.57 |
| Control - no NMES | KOOS Pain | 80.38 z-score | Standard Deviation 15.43 |
KOOS - PS
Functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS) Physical Function Shortform (PS) questionnaire. Change in total score from baseline to 12 weeks postoperative score. Minimum value is 0, maximum value is 100, and higher values mean greater improvement over baseline total score.
Time frame: 12 weeks
Population: Numbers do not match Participant Flow because data were missing.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NMES Preoperative and Postoperative | KOOS - PS | 33.43 units on a scale | Standard Deviation 14.76 |
| NMES Postoperative Only | KOOS - PS | 20.39 units on a scale | Standard Deviation 12.7 |
| Control - no NMES | KOOS - PS | 26.62 units on a scale | Standard Deviation 9.81 |
Number of Outpatient Therapy Visits (Patient Questionnaire)
Difference in number of outpatient therapy visits among the treatment groups
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NMES Preoperative and Postoperative | Number of Outpatient Therapy Visits (Patient Questionnaire) | 12.86 visits | Standard Deviation 4.95 |
| NMES Postoperative Only | Number of Outpatient Therapy Visits (Patient Questionnaire) | 16.25 visits | Standard Deviation 7.29 |
| Control - no NMES | Number of Outpatient Therapy Visits (Patient Questionnaire) | 11.67 visits | Standard Deviation 5.06 |
Number of Patients Discharged to Extended Care Facility
Patent discharge other than home to extended care facility
Time frame: 12 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NMES Preoperative and Postoperative | Number of Patients Discharged to Extended Care Facility | 0 Participants |
| NMES Postoperative Only | Number of Patients Discharged to Extended Care Facility | 0 Participants |
| Control - no NMES | Number of Patients Discharged to Extended Care Facility | 1 Participants |
Number of Patients Readmitted to Hospital
Number of all-cause readmissions to the hospital
Time frame: 12 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NMES Preoperative and Postoperative | Number of Patients Readmitted to Hospital | 0 Participants |
| NMES Postoperative Only | Number of Patients Readmitted to Hospital | 0 Participants |
| Control - no NMES | Number of Patients Readmitted to Hospital | 1 Participants |
Visual Analogue Scale (VAS) Pain Level (0-10 Scale)
Differences in VAS scores between the treatment groups from baseline to 12 weeks postop. Higher score represents worse pain.
Time frame: 12 weeks
Population: Numbers do not match Participant Flow because data were missing.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NMES Preoperative and Postoperative | Visual Analogue Scale (VAS) Pain Level (0-10 Scale) | 2.00 units on a scale | Standard Deviation 2.92 |
| NMES Postoperative Only | Visual Analogue Scale (VAS) Pain Level (0-10 Scale) | 1.80 units on a scale | Standard Deviation 2.04 |
| Control - no NMES | Visual Analogue Scale (VAS) Pain Level (0-10 Scale) | 1.18 units on a scale | Standard Deviation 2.36 |